Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With First Line Trastuzumab, Pertuzumab and Taxanes Based Regimen

NCT02101879 is registered in ClinicalTrials.gov with Rambam Health Care Campus as lead sponsor.

NCT NCT02101879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02101879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With First Line Trastuzumab, Pertuzumab and Taxanes Based Regimen
Lead sponsor
Rambam Health Care Campus
Phase
Observational
Overall status
Unknown status
Start date
May 31, 2014
Completion date
August 31, 2016
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anti her2 therapy., cardiotoxicity., metastatic breast cancer